Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 18, Issue 6, Pages 590-597
Publisher
Wiley
Online
2016-03-03
DOI
10.1111/dom.12654
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study
- (2016) Michael A Weber et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
- (2015) Michael A. Weber et al. BLOOD PRESSURE
- The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers
- (2015) Bauke Schievink et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
- (2015) C David Sjöström et al. Diabetes & Vascular Disease Research
- Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers
- (2015) Bauke Schievink et al. European Journal of Preventive Cardiology
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
- (2015) Dick de Zeeuw et al. Lancet Diabetes & Endocrinology
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
- (2014) H. J. Lambers Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
- (2014) D. de Zeeuw et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Telmisartan Attenuates Diabetic Nephropathy by Suppressing Oxidative Stress in db/db Mice
- (2013) Chikage Sato-Horiguchi et al. NEPHRON EXPERIMENTAL NEPHROLOGY
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Effects of Dapagliflozin on Cardiovascular Risk Factors
- (2013) Agata Ptaszynska et al. POSTGRADUATE MEDICINE
- Sodium glucose cotransporter 2 and the diabetic kidney
- (2012) Muralikrishna Gangadharan Komala et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
- (2011) Frank A. Holtkamp et al. KIDNEY INTERNATIONAL
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
- (2009) B Komoroski et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
- (2008) Hans-Henrik Parving et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now